{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:12:29Z","timestamp":1791573149425,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Health & Medical Research Council with a Centre of Research Excellence","award":["APP1197652"],"award-info":[{"award-number":["APP1197652"]}]},{"name":"National Health & Medical Research Council with a Centre of Research Excellence","award":["APP1197652"],"award-info":[{"award-number":["APP1197652"]}]},{"name":"National Health & Medical Research Council with a Centre of Research Excellence","award":["APP1197652"],"award-info":[{"award-number":["APP1197652"]}]},{"name":"Cancer Australia Priority-driven Collaborative Cancer Research Scheme","award":["1163065"],"award-info":[{"award-number":["1163065"]}]},{"name":"Cancer Australia Priority-driven Collaborative Cancer Research Scheme","award":["1163065"],"award-info":[{"award-number":["1163065"]}]},{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]},{"name":"iCare Dust Diseases Board Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03889-x","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:49:04Z","timestamp":1735879744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Fractionated low-dose radiotherapy primes the tumor microenvironment for immunotherapy in a murine mesothelioma model"],"prefix":"10.1007","volume":"74","author":[{"given":"Rebecca A.","family":"D\u2019Alonzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synat","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suki","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pejman","family":"Rowshanfarzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"3889_CR1","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K et al (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27:S87\u2013S97. https:\/\/doi.org\/10.3747\/co.27.5223","journal-title":"Curr Oncol"},{"key":"3889_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.lungcan.2021.11.006","volume":"162","author":"AK Nowak","year":"2021","unstructured":"Nowak AK, Chin WL, Keam S, Cook A (2021) Immune checkpoint inhibitor therapy for malignant pleural mesothelioma. Lung Cancer 162:162\u2013168. https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.006","journal-title":"Lung Cancer"},{"key":"3889_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fonc.2020.00126","volume":"10","author":"AK Nowak","year":"2020","unstructured":"Nowak AK, Brosseau S, Cook A, Zalcman G (2020) Antiangiogeneic strategies in mesothelioma. Front. Oncol 10:126. https:\/\/doi.org\/10.3389\/fonc.2020.00126","journal-title":"Oncol"},{"issue":"3","key":"3889_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semradonc.2004.04.008","volume":"14","author":"P Vaupel","year":"2004","unstructured":"Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14(3):198. https:\/\/doi.org\/10.1016\/j.semradonc.2004.04.008","journal-title":"Semin Radiat Oncol"},{"key":"3889_CR5","doi-asserted-by":"publisher","first-page":"111607","DOI":"10.1016\/j.biopha.2021.111607","volume":"139","author":"Z Liu","year":"2021","unstructured":"Liu Z et al (2021) Vascular normalization in immunotherapy: a promising mechanisms combined with radiotherapy. Biomed Pharmacother 139:111607. https:\/\/doi.org\/10.1016\/j.biopha.2021.111607","journal-title":"Biomed Pharmacother"},{"key":"3889_CR6","doi-asserted-by":"publisher","first-page":"613114","DOI":"10.3389\/fimmu.2020.613114","volume":"11","author":"R Abou Khouzam","year":"2020","unstructured":"Abou Khouzam R et al (2020) Tumor hypoxia regulates immune escape\/invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies. Front Immunol 11:613114. https:\/\/doi.org\/10.3389\/fimmu.2020.613114","journal-title":"Front Immunol"},{"key":"3889_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","volume":"502","author":"NE Donlon","year":"2021","unstructured":"Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J (2021) Radiotherapy, immunotherapy, and the tumor microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett 502:84\u201396. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.045","journal-title":"Cancer Lett"},{"key":"3889_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mc.23360","volume":"61","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T, Young KH (2022) Effects of radiation on tumor vasculature. Mol Carcinog 61:165\u2013172. https:\/\/doi.org\/10.1002\/mc.23360","journal-title":"Mol Carcinog"},{"key":"3889_CR9","doi-asserted-by":"publisher","first-page":"76613","DOI":"10.18632\/oncotarget.12814","volume":"7","author":"EA Kleibeuker","year":"2016","unstructured":"Kleibeuker EA et al (2016) Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget 7:76613\u201376627. https:\/\/doi.org\/10.18632\/oncotarget.12814","journal-title":"Oncotarget"},{"key":"3889_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers12010121","volume":"12","author":"K Cl\u00e9ment-Colmou","year":"2020","unstructured":"Cl\u00e9ment-Colmou K et al (2020) Influence of radiotherapy fractionation schedule on the tumor vascular microenvironment in prostate and lung cancer models. Cancers (Basel) 12:12. https:\/\/doi.org\/10.3390\/cancers12010121","journal-title":"Cancers (Basel)"},{"key":"3889_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.05.005","volume":"457","author":"V Potiron","year":"2019","unstructured":"Potiron V et al (2019) Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy. Cancer Lett 457:1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.005","journal-title":"Cancer Lett"},{"key":"3889_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/1179064418761639","author":"KM Arnold","year":"2018","unstructured":"Arnold KM et al (2018) The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer Growth Metastasis. https:\/\/doi.org\/10.1177\/1179064418761639","journal-title":"Cancer Growth Metastasis"},{"key":"3889_CR13","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3389\/fimmu.2018.03107","volume":"9","author":"RSA Goedegebuure","year":"2018","unstructured":"Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL (2018) Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer? Front Immunol 9:3107. https:\/\/doi.org\/10.3389\/fimmu.2018.03107","journal-title":"Front Immunol"},{"key":"3889_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/jitc-2020-000537","volume":"8","author":"HB Barsoumian","year":"2020","unstructured":"Barsoumian HB et al (2020) Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer 8:2. https:\/\/doi.org\/10.1136\/jitc-2020-000537","journal-title":"J Immunother Cancer"},{"key":"3889_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3631","author":"RB Patel","year":"2021","unstructured":"Patel RB et al (2021) Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb3631","journal-title":"Sci Transl Med"},{"key":"3889_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG et al (2022) Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov 12:108\u2013133. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0003","journal-title":"Cancer Discov"},{"key":"3889_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd9882","author":"J Murakami","year":"2021","unstructured":"Murakami J et al (2021) Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd9882","journal-title":"Sci Transl Med"},{"key":"3889_CR18","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1158\/1078-0432.CCR-17-0438","volume":"23","author":"L De La Maza","year":"2017","unstructured":"De La Maza L et al (2017) In situ vaccination after accelerated hypofractionated radiation and surgery in a mesothelioma mouse model. Clin Cancer Res 23:5502\u20135513. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0438","journal-title":"Clin Cancer Res"},{"key":"3889_CR19","doi-asserted-by":"publisher","first-page":"e1169","DOI":"10.1002\/cti2.1169","volume":"9","author":"S Keam","year":"2020","unstructured":"Keam S, Gill S, Ebert MA, Nowak AK, Cook AM (2020) Enhancing the efficacy of immunotherapy using radiotherapy. Clin Transl Immunology 9:e1169. https:\/\/doi.org\/10.1002\/cti2.1169","journal-title":"Clin Transl Immunology"},{"key":"3889_CR20","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ et al (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74:5458\u20135468. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1258","journal-title":"Cancer Res"},{"key":"3889_CR21","doi-asserted-by":"publisher","first-page":"e84076","DOI":"10.1371\/journal.pone.0084076","volume":"8","author":"VA Potiron","year":"2013","unstructured":"Potiron VA et al (2013) Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer. PLoS ONE 8:e84076. https:\/\/doi.org\/10.1371\/journal.pone.0084076","journal-title":"PLoS ONE"},{"key":"3889_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.radonc.2019.06.035","volume":"141","author":"F Gil Marques","year":"2019","unstructured":"Gil Marques F et al (2019) Low doses of ionizing radiation activate endothelial cells and induce angiogenesis in peritumoral tissues. Radiother Oncol 141:256\u2013261. https:\/\/doi.org\/10.1016\/j.radonc.2019.06.035","journal-title":"Radiother Oncol"},{"key":"3889_CR23","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s00432-012-1263-6","volume":"138","author":"B Hohlweg-Majert","year":"2012","unstructured":"Hohlweg-Majert B et al (2012) Impact of radiotherapy on microsurgical reconstruction of the head and neck. J Cancer Res Clin Oncol 138:1799\u20131811. https:\/\/doi.org\/10.1007\/s00432-012-1263-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"3889_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.radonc.2021.06.037","volume":"162","author":"RR Patel","year":"2021","unstructured":"Patel RR et al (2021) High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial. Radiother Oncol 162:60\u201367. https:\/\/doi.org\/10.1016\/j.radonc.2021.06.037","journal-title":"Radiother Oncol"},{"key":"3889_CR25","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379\u20135388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0265","journal-title":"Clin Cancer Res"},{"key":"3889_CR26","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","volume":"9","author":"S Demaria","year":"2021","unstructured":"Demaria S et al (2021) Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother.Cancer 9:e002038. https:\/\/doi.org\/10.1136\/jitc-2020-002038","journal-title":"J Immunother.Cancer"},{"key":"3889_CR27","doi-asserted-by":"publisher","first-page":"12468","DOI":"10.18632\/oncotarget.3487","volume":"6","author":"L Wu","year":"2015","unstructured":"Wu L et al (2015) Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget 6:12468\u201312480. https:\/\/doi.org\/10.18632\/oncotarget.3487","journal-title":"Oncotarget"},{"key":"3889_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397:375\u2013386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"key":"3889_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.2910520609","volume":"52","author":"MR Davis","year":"1992","unstructured":"Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW (1992) Establishment of a murine model of malignant mesothelioma. Int J Cancer 52:881\u2013886. https:\/\/doi.org\/10.1002\/ijc.2910520609","journal-title":"Int J Cancer"},{"key":"3889_CR30","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","volume":"171","author":"C Jackaman","year":"2003","unstructured":"Jackaman C et al (2003) IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 171:5051\u20135063. https:\/\/doi.org\/10.4049\/jimmunol.171.10.5051","journal-title":"J Immunol"},{"key":"3889_CR31","first-page":"1071","volume":"59","author":"AL Marzo","year":"1999","unstructured":"Marzo AL, Lake RA, Robinson BW, Scott B (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59:1071\u20131107","journal-title":"Cancer Res"},{"key":"3889_CR32","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1118\/1.1374247","volume":"28","author":"CM Ma","year":"2001","unstructured":"Ma CM et al (2001) AAPM protocol for 40\u2013300 kV x-ray beam dosimetry in radiotherapy and radiobiology. Med Phys 28:868\u2013893. https:\/\/doi.org\/10.1118\/1.1374247","journal-title":"Med Phys"},{"key":"3889_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s13246-019-00755-4","volume":"42","author":"TV Feddersen","year":"2019","unstructured":"Feddersen TV, Rowshanfarzad P, Abel TN, Ebert MA (2019) Commissioning and performance characteristics of a pre-clinical image-guided radiotherapy system. Australas Phys Eng Sci Med 42:541\u2013551. https:\/\/doi.org\/10.1007\/s13246-019-00755-4","journal-title":"Australas Phys Eng Sci Med"},{"key":"3889_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray NL, Pimentel H, Melsted P, Pachter L (2016) Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34:525\u2013527. https:\/\/doi.org\/10.1038\/nbt.3519","journal-title":"Nat Biotechnol"},{"issue":"4","key":"3889_CR35","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.2","volume":"30","author":"C Soneson","year":"2015","unstructured":"Soneson C, Love MI, Robinson MD (2015) Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research 30(4):1521. https:\/\/doi.org\/10.12688\/f1000research.7563.2","journal-title":"F1000Research"},{"key":"3889_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"3889_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY et al (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinfo 14:128. https:\/\/doi.org\/10.1186\/1471-2105-14-128","journal-title":"BMC Bioinfo"},{"key":"3889_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711:243\u2013259. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12","journal-title":"Methods Mol Biol"},{"key":"3889_CR39","doi-asserted-by":"publisher","first-page":"40508","DOI":"10.1038\/srep40508","volume":"7","author":"Z Chen","year":"2017","unstructured":"Chen Z et al (2017) Inference of immune cell composition on the expression profiles of mouse tissue. Sci Rep 7:40508. https:\/\/doi.org\/10.1038\/srep40508","journal-title":"Sci Rep"},{"issue":"6","key":"3889_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/s0197-2456(98)00037-3","volume":"19","author":"WD Dupont","year":"1998","unstructured":"Dupont WD, Plummer WD Jr (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19(6):589\u2013601. https:\/\/doi.org\/10.1016\/s0197-2456(98)00037-3","journal-title":"Control Clin Trials"},{"key":"3889_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/09553002.2021.1900943","volume":"97","author":"RA D\u2019Alonzo","year":"2021","unstructured":"D\u2019Alonzo RA et al (2021) In vivo noninvasive preclinical tumor hypoxia imaging methods: a review. Int J Radiat Biol 97:593\u2013631. https:\/\/doi.org\/10.1080\/09553002.2021.1900943","journal-title":"Int J Radiat Biol"},{"key":"3889_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.celrep.2019.12.013","volume":"30","author":"B He","year":"2020","unstructured":"He B et al (2020) Remodeling of metastatic vasculature reduces lung colonization and sensitizes overt metastases to immunotherapy. Cell Rep 30:714-724.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.013","journal-title":"Cell Rep"},{"key":"3889_CR43","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1667\/RR3116.1","volume":"179","author":"J Lan","year":"2013","unstructured":"Lan J et al (2013) Ablative hypofractionated radiotherapy normalizes tumor vasculature in lewis lung carcinoma mice model. Radiat Res 179:458\u2013464. https:\/\/doi.org\/10.1667\/RR3116.1","journal-title":"Radiat Res"},{"key":"3889_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F et al (2013) Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24:589\u2013602. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.014","journal-title":"Cancer Cell"},{"key":"3889_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/carcin\/bgw007","volume":"37","author":"H Prakash","year":"2016","unstructured":"Prakash H et al (2016) Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma. Carcinogenesis 37:301\u2013313. https:\/\/doi.org\/10.1093\/carcin\/bgw007","journal-title":"Carcinogenesis"},{"key":"3889_CR46","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/mc.22879","volume":"57","author":"V Nadella","year":"2018","unstructured":"Nadella V et al (2018) Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium. Mol Carcinog 57:1664\u20131671. https:\/\/doi.org\/10.1002\/mc.22879","journal-title":"Mol Carcinog"},{"issue":"4","key":"3889_CR47","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1136\/jitc-2020-002032","volume":"30","author":"JHA Creemers","year":"2021","unstructured":"Creemers JHA, Lesterhuis WJ, Mehra N et al (2021) A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. J Immunother Cancer 30(4):877\u2013882. https:\/\/doi.org\/10.1136\/jitc-2020-002032","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3889_CR48","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/1078-0432.CCR-23-1572","volume":"30","author":"D Dejardin","year":"2024","unstructured":"Dejardin D, Kraxner A, Blank A, Rieder N, Teichgr\u00e4ber V et al (2024) A composite decision rule of CD8+ T-cell density in tumor biopsies predicts efficacy in early-stage. Immunother Trials Clin Cancer Res 30(4):877\u2013882. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1572","journal-title":"Immunother Trials Clin Cancer Res"},{"issue":"41","key":"3889_CR49","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1016\/j.eclinm.2021.101134","volume":"16","author":"F Li","year":"2021","unstructured":"Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B et al (2021) The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine 16(41):101134. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101134","journal-title":"EClinicalMedicine"},{"issue":"153","key":"3889_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.lungcan.2021.01.013","volume":"1","author":"S Hashemi","year":"2021","unstructured":"Hashemi S, Fransen MF, Niemeijer A, Ben Taleb N, Houda I, Veltman J et al (2021) Surprising impact of stromal TIL\u2019s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer 1(153):81\u201389. https:\/\/doi.org\/10.1016\/j.lungcan.2021.01.013","journal-title":"Lung Cancer"},{"key":"3889_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ctro.2020.12.006","volume":"27","author":"WA Mampuya","year":"2021","unstructured":"Mampuya WA et al (2021) Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. Clinical Trans Radiat Oncol 27:85\u201388. https:\/\/doi.org\/10.1016\/j.ctro.2020.12.006","journal-title":"Clinical Trans Radiat Oncol"},{"key":"3889_CR52","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22159","author":"R Rittberg","year":"2022","unstructured":"Rittberg R, Chan E, Yip S, Alex D, Ho C (2022) Radiation induced abscopal effect in a patient with malignant pleural mesothelioma on pembrolizumab. Cureus. https:\/\/doi.org\/10.7759\/cureus.22159","journal-title":"Cureus"},{"key":"3889_CR53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","volume":"23","author":"JE Kim","year":"2017","unstructured":"Kim JE et al (2017) Combination therapy with anti-PD-1, Anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 23:124\u2013136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1535","journal-title":"Clin Cancer Res"},{"key":"3889_CR54","doi-asserted-by":"publisher","first-page":"715234","DOI":"10.3389\/fimmu.2021.715234","volume":"12","author":"JS Dolina","year":"2021","unstructured":"Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S (2021) CD8+ T cell exhaustion in cancer. Front Immunol 12:715234. https:\/\/doi.org\/10.3389\/fimmu.2021.715234","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03889-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03889-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:53:53Z","timestamp":1739174033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03889-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3889"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03889-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experimental protocols involving mice were approved by the Animal Ethics Committees of HPIMR, the University of Western Australia (UWA), and the Telethon Kids Institute (Perth, Australia) (AE163) and were conducted in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes (8th edition, 2013) and UWA animal ethics guidelines and protocols.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"44"}}